FATE

FATE THERAPEUTICS INC FATE

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,881 of 2,925

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$2.08M

Quarter to Jun 30

Net income

$-30.16M

Quarter to Jun 30

Free cash flow

$-23.48M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$193.18M total
Redmile Group, LLC
$34.76M0.0%
BlackRock, Inc.
$19.71M-27.5%
VANGUARD PORTFOLIO MANAGEMENT LLC
$12.27M+9.9%
VANGUARD CAPITAL MANAGEMENT LLC
$12.00M+6.0%
ACADIAN ASSET MANAGEMENT LLC
$11.74M+5.6%
AQR CAPITAL MANAGEMENT LLC
$10.36M+27.8%
TWO SIGMA INVESTMENTS, LP
$9.69M+3.6%
JOHNSON & JOHNSON
$9.12M0.0%
RENAISSANCE TECHNOLOGIES LLC
$8.05M+0.3%
MILLENNIUM MANAGEMENT LLC
$6.57MNew
GOLDMAN SACHS GROUP INC
$5.53M+54.3%
GEODE CAPITAL MANAGEMENT, LLC
$3.57M-49.0%
T. Rowe Price Investment Management, Inc.
$2.92MNew
JANE STREET GROUP, LLC
$2.77M+58.7%
CITADEL ADVISORS LLC
$2.68M+5.3%
Bruce & Co., Inc.
$2.67M+25.3%
MORGAN STANLEY
$1.88M-9.5%
VANGUARD FIDUCIARY TRUST CO
$1.73M-2.0%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$1.65M-19.2%
UBS Group AG
$1.59M-67.6%
Qube Research & Technologies Ltd
$1.56MNew
Connor, Clark & Lunn Investment Management Ltd.
$1.55M+22.4%
STATE STREET CORP
$1.51M-75.3%
DAFNA Capital Management LLC
$1.42M-4.5%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.38M+71.2%
See all 156 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FATE

Earnings Per Share

13fpro.ai/company/FATE

Loading ratio trend…

FATE key financials by period

Reported revenue, net income and operating margin by fiscal year, from FATE THERAPEUTICS INC's annual filings on SEC EDGAR.

FATE THERAPEUTICS INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$6.6M$-136.3M—
FY 2024$13.6M$-186.3M—
FY 2023$63.5M$-160.9M—
FY 2022$96.3M$-281.7M—
FY 2021$55.8M$-212.2M—
FY 2020$31.4M$-173.4M—
Source: FATE filings on SEC EDGAR →

Companies similar to FATE

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

FATE insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in FATE

1 transaction in FATE reported by 1 member of Congress under the STOCK Act, most recent trade Jan 31, 2023. Reported transactions, not recommendations.

All Congress stock trades →

About FATE THERAPEUTICS INC (FATE): stock profile, AI score and financials

FATE THERAPEUTICS INC (FATE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FATE at 9.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,881 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (1.6) and profitability (1.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), FATE THERAPEUTICS INC reports quarterly revenue of $2.1M, net income of $-30.2M, free cash flow of $-23.5M. Top institutional holders of FATE by reported 13-F value include Redmile Group, BlackRock, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. FATE trades on the Nasdaq exchange and files with the SEC under CIK 1434316. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FATE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FATE THERAPEUTICS INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1434316 →